, "type": "ref", "volume": "12", "year": "2017"}, "text": "Discontinuation of disease modifying treatments in middle aged multiple sclerosis patients. First line drugs vs natalizumab", "sentences": [], "annotations": [], "relations": []}, {"offset": 51931, "infons": {"fpage": "2214", "issue": "22", "lpage": "2216", "name_0": "surname:Rigau;given-names:V", "name_1": "surname:Mania;given-names:A", "name_2": "surname:Befort;given-names:P", "pub-id_pmid": "23100404", "section_type": "REF", "source": "Neurology", "type": "ref", "volume": "79", "year": "2012"}, "text": "Lethal multiple sclerosis relapse after natalizumab withdrawal", "sentences": [], "annotations": [], "relations": []}, {"offset": 51994, "infons": {"fpage": "1647", "issue": "11", "lpage": "1649", "name_0": "surname:Daelman;given-names:L", "name_1": "surname:Maitrot;given-names:A", "name_2": "surname:Maarouf;given-names:A", "name_3": "surname:Chaunu;given-names:M", "name_4": "surname:Papeix;given-names:C", "name_5": "surname:Tourbah;given-names:A", "section_type": "REF", "source": "Mult Sclers J", "type": "ref", "volume": "18", "year": "2012"}, "text": "Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal", "sentences": [], "annotations": [], "relations": []}, {"offset": 52088, "infons": {"fpage": "35", "issue": "1", "lpage": "39", "name_0": "surname:Baumgartner;given-names:A", "name_1": "surname:Stich;given-names:O", "name_2": "surname:Rauer;given-names:S", "pub-id_pmid": "21913869", "section_type": "REF", "source": "Int J Neurosci", "type": "ref", "volume": "122", "year": "2012"}, "text": "Clinical and radiological disease reactivation after cessation of long-term therapy with natalizumab", "sentences": [], "annotations": [], "relations": []}, {"offset": 52189, "infons": {"fpage": "e297", "issue": "6", "name_0": "surname:Papeix;given-names:C", "name_1": "surname:Vukusic;given-names:S", "name_2": "surname:Casey;given-names:R", "pub-id_pmid": "27844037", "section_type": "REF", "source": "Neurol Neuroimmunol Neuroinflamm", "type": "ref", "volume": "3", "year": "2016"}, "text": "Risk of relapse after natalizumab withdrawal: Results from the French TYSEDMUS cohort", "sentences": [], "annotations": [], "relations": []}, {"offset": 52275, "infons": {"fpage": "15", "issue": "1", "lpage": "23", "name_0": "surname:Miller;given-names:DH", "name_1": "surname:Khan;given-names:OA", "name_2": "surname:Sheremata;given-names:WA", "pub-id_pmid": "12510038", "section_type": "REF", "source": "N Engl J Med", "type": "ref", "volume": "348", "year": "2003"}, "text": "A controlled trial of natalizumab for relapsing multiple sclerosis", "sentences": [], "annotations": [], "relations": []}, {"offset": 52342, "infons": {"fpage": "806", "issue": "9", "lpage": "812", "name_0": "surname:Goodman;given-names:AD", "name_1": "surname:Rossman;given-names:H", "name_2": "surname:Bar-Or;given-names:A", "pub-id_pmid": "19255407", "section_type": "REF", "source": "Neurology", "type": "ref", "volume": "72", "year": "2009"}, "text": "GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study", "sentences": [], "annotations": [], "relations": []}, {"offset": 52423, "infons": {"fpage": "29", "issue": "1", "lpage": "39", "name_0": "surname:Kappos;given-names:L", "name_1": "surname:Radue;given-names:EW", "name_2": "surname:Comi;given-names:G", "pub-id_pmid": "26024899", "section_type": "REF", "source": "Neurology", "type": "ref", "volume": "85", "year": "2015"}, "text": "Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS", "sentences": [], "annotations": [], "relations": []}, {"offset": 52512, "infons": {"file": "t1-ndt-13-1691.xml", "id": "t1-ndt-13-1691", "section_type": "TABLE", "type": "table_caption"}, "text": "Review of natalizumab Phase III clinical trials", "sentences": [], "annotations": [], "relations": []}, {"offset": 52560, "infons": {"file": "t1-ndt-13-1691.xml", "id": "t1-ndt-13-1691", "section_type": "TABLE", "type": "table", "xml": "<?xml version=\"1.